Cardiovascular Diseases after Kidney Transplantation in Korea by Jeong, Jong Cheol et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Cardiovascular Diseases after Kidney Transplantation in Korea
Cardiovascular disease (CVD) is the leading cause of death in renal allograft recipients with 
functioning graft. Our study aimed to determine the incidence and the risk factors of 
cardiovascular disease after renal transplantation in Korea. We retrospectively analyzed 430 
adult recipients who underwent kidney transplantation between January 1997 and 
February 2007. CVD was defined as a composite outcome of ischemic heart disease, 
cerebrovascular accident and peripheral vascular disease. Mean age of recipients was 
40.0±11.8 yr. Mean duration of follow-up was 72±39 months. The cumulative incidence of 
CVD after renal transplantation was 2.4% at 5 yr, 5.4% at 10 yr and 11.4% at 12 yr. 
Multivariate analysis revealed that recipient’s age, diabetes mellitus and duration of dialysis 
before transplantation were associated with post-transplant CVD (hazard ratio 1.843 [95% 
CI, 1.005-3.381], 3.846 [95% CI, 1.025-14.432] and 3.394 [95% CI, 1.728-6.665] 
respectively). In conclusion, old age, duration of dialysis and diabetes mellitus are important 
risk factors for post-transplant CVD, although the incidence of post-renal transplant CVD is 
lower in Korea than that in western countries.
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INTRODUCTION
Kidney transplantation is now one of the standard treatment 
options of end stage renal disease patients, which can give op-
portunities even for highly sensitized patients (1, 2). Cardiovas-
cular disease is the leading cause of death in renal allograft re-
cipients with functioning graft (3). There were approximately 6- 
and 10-fold higher incidences in adult allograft recipients, com-
paring that of the general population (4). In a recent report, car-
diovascular disease, including angina pectoris, cerebrovascular 
accident (CVA) and peripheral vascular disease (PVD), occurred 
in 25% of the patients at 10 yr and 53% of the patients at 15 yr af-
ter renal transplantation (5). Another study based on the United 
States Renal Data System (USRDS), myocardial infarction (MI) 
after kidney transplantation occurred in 11.1% of patients by 3 
yr post-transplantation. However, there was no report about the 
incidence of cardiovascular disease after renal transplantation 
in Asian population, although ethnic disparity in the incidence 
of cardiovascular disease exists (6). 
  Renal allograft recipients have a higher prevalence of tradi-
tional Framingham atherosclerotic vascular disease risk factors 
(7). In addition to traditional risk factors, variables related to end 
stage renal disease (ESRD), allograft function, donor and im-
munosuppression are also important risk factors for cardiovas-
cular disease (4, 5, 8, 9). Although there was a recent attempt to 
find clinical risk factors to the progression of coronary athero-
sclerosis score (10), significance of risk factors of cardiovascular 
disease, either traditional or nontraditional, has not been evalu-
ated in Asian renal allograft recipients. Our study aimed to de-
termine the incidence and the risk factors of cardiovascular 
disease after renal transplantation in Korea.  
MATERIALS AND METHODS
Subjects
Medical records of 554 patients who underwent renal trans-
plantation between January 1996 and February 2007 at Seoul 
National University Hospital were reviewed retrospectively. Data 
of 124 patients were excluded from analysis for various reasons: 
age younger than 18 yr (n=94), combined organ transplantation 
(n=15, 13 for simultaneous pancreas-kidney co-transplantation, 
one for liver-kidney co-transplantation, and one for heart-kid-
ney co-transplantation) and unavailable medical records (n=14). 
Finally, 430 patients were included in the study. Institutional 
review board of Seoul National University Hospital approved 
this study (IRB No:H-1002-001-307). The study is conducted 
under the Declaration of Helsinki. 
Definitions
Cardiovascular disease was defined as a composite outcome of Jeong JC, et al.  •  Cardiovascular Diseases after Kidney Transplantation
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ischemic heart disease (IHD), CVA and PVD. The diagnosis of 
IHD included angina pectoris, coronary artery revasculariza-
tion (percutaneous coronary intervention or coronary artery 
bypass grafting), MI, or death attributable to IHD. Angina pec-
toris was accepted when it was verified by medical records with 
objective evidence (abnormal coronary angiography or myo-
cardial scintigraphy). MI was diagnosed by a history of typical 
chest pain and myocardial enzyme elevation. CVA was defined 
as a composite outcome of ischemic stroke or documented tran-
sient ischemic attack. Intracerebral hemorrhage (ICH) was ex-
cluded. PVD was limited to lesions that needed revasculariza-
tion. In the case of diabetic foot, only amputation was accepted 
as PVD. 
Clinical variables
Variables recorded at the time of transplantation included: age, 
gender, weight, height, body mass index (BMI, kg/m
2), cause of 
ESRD, modality of renal replacement therapy (RRT), duration 
of RRT, donor type (deceased/living), donor age, donor gender, 
number of HLA mismatches, cigarette smoking history, diabe-
tes mellitus, hypertension, dyslipidemia, previous cardiovascu-
lar diseases (IHD, CVA or PVD), baseline echocardiographic 
finding and type of initial calcineurin inhibitor (cyclosporine A 
vs FK-506). 
  Post-transplant variables were as follows: the development 
of post-transplant diabetes mellitus (PTDM) and glomerular 
filtration rate (GFR) at one year determined by using simplified 
Modification of Diet in Renal Disease (MDRD) study equation.
Statistical analysis
Continuous variables were expressed as arithmetic mean±SD. 
Chi-square test (or Fisher’s exact test) and independent t-test 
were carried out to compare the characteristics of population 
between patients with cardiovascular disease and patients with-
out, as appropriate. Univariate Cox regression analysis was per-
formed to find risk factors of cardiovascular disease. Risk factors 
with a P value of <0.20 were kept to be included in multivariate 
analysis. Multivariate analysis was performed using Cox regres-
sion models. Variables that showed a missing rate of over 10% 
were not accepted into the multivariate analysis model. Kaplan-
Meier survival curves were also generated. The survival curves 
between diabetes patients and non-diabetes patients were com-
pared by Log-rank test. A P value of <0.05 was considered sta-
tistically significant. All statistical analyses were performed us-
ing the SPSS statistics package version 12.0 (SPSS Inc, Chicago, 
IL, USA). 
RESULTS
Baseline characteristics
In 430 patients, mean age was 40±11.8 yr and 63% were men. 
Mean body mass index was 22±3.0 kg/m
2. The most common 
cause of ESRD was glomerulonephritis (31.4%), followed by hy-
pertension (12.8%), diabetes (7.2%), and autosomal dominant 
polycystic kidney disease (ADPKD) (2.3%). Patients had a his-
tory of smoking or were still smoking at the time of transplanta-
tion in 23.4%. Most of patients (91.2%) were hypertensive before 
transplantation. Diabetes mellitus was prevalent in 9.8% of pa-
tients. Mean duration of diabetes mellitus was 13.4±8.3 yr. PTDM 
occurred in 15.7% of patients. Most PTDM (67%) occurred with-
in three months after renal transplantation. PTDM was more 
prevalent in patients who used FK-506, but it did not show sta-
tistical significance (19.5% vs 12.9%, P=0.092). Patients previ-
ously diagnosed as IHD and CVA were 3.8% and 3.7%, respec-
tively. 
  The majority of patients were transplanted with a living donor 
kidney (84.4%). Mean donor age was 37±11.2 yr. Sixteen percent 
of patients underwent kidney transplantation without dialysis 
(preemptive transplantation). In patients who had received di-
alysis, the mean duration of RRT was 30.9±42.48 months. All 
patients received calcineurin inhibitor-based immunosuppres-
sion (FK-506 vs cyclosporine A, 43.1%:56.9%, as initial calcineu-
rin inhibitor). 
Incidence of cardiovascular disease after renal 
transplantation
CVD occurred in 16 patients during follow up. The mean dura-
tion of follow up was 72±39 months (range, 0-156 months). Fig. 
1 shows the cumulative incidence of CVD after renal transplan-
tation: 2.4% at 5 yr, 5.4% at 10 yr, and 11.4% at 12 yr. Table 1 de-
scribes detailed information of CVD. CVD occurred in various 
time periods (range 0-131 months). MI occurred in five patients 
and two of them died. The other mortality occurred in a PVD 
patient due to an infection. 
  Table 2 summarizes the differences of baseline clinical char-
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Fig. 1. The cumulative incidence of cardiovascular disease after renal transplantation. 
The estimated percentage equals 2.4% after 5 yr, 5.4% after 10 yr and 11.4% after 
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acteristics between CVD (n=16) and non-CVD (n=414) groups. 
Mean age of CVD group was about 10 yr higher than that of non-
CVD group (49±10.8 vs 40±11.7 yr, P=0.003). Diabetes was more 
prevalent in CVD group (31.3% vs 8.9%, P=0.014). More patients 
in CVD group had left ventricular dysfunction (defined by an 
ejection fraction less than 45% on echocardiography, 37.5% vs 
5.8%, P=0.011). The duration of RRT was longer in CVD group 
(52.1±43.69 vs 29.9±42.23 months, P=0.041). However, other 
variables such as gender proportion, weight, BMI, history of 
Table 1. Clinical characteristics of cardiovascular disease after renal transplantation
No.
Gender/ 
Age (yr)
Type of CVD 
Interval between transplantation 
and CVD (months)
Management Outcomes
Interval between 
transplantation and  
death (months)
  1 M/64 MI <1 month PCI Death   9 months
  2 M/51 MI 52 months PCI Alive
  3 M/49 MI 18 months Medical management Death 29 months
  4 M/49 MI 131 months Medical management Alive
  5 F/49 MI 68 months Medical management Alive
  6 M/57 Angina 138 months PCI Alive
  7 M/52 Angina 22 months Medical management Alive
  8 M/46 Angina 23 months Medical management Alive
  9 F/45 Angina 115 months Medical management Alive
10 F/61 Brain infarct 5 months Medical management Alive
11 F/57 Brain infarct 122 months Medical management Alive
12 F/24 Brain infarct 77 months Medical management Alive
13 M/59 TIA  28 months Medical management Alive
14 M/44 Diabetic foot 14 months Amputation Alive
15 M/41 Diabetic foot 36 months Amputation Death 54 months
16 M/29 Renal artery stenosis 91 months Stent insertion Alive
CVD, cardiovascular disease; MI, myocardial infarct; PCI, Percutaneous coronary intervention; TIA, transient ischemic attack.
Table 2. Comparison of baseline characteristics of renal allograft recipients
Cardiovascular 
disease group
Non-
cardiovascular 
disease group
P
Number 16 414
Age (yr)    49±10.8    40±11.7 0.003
Male gender (%) 68.8 62.8 0.794
Weight (kg) 59.1±8.75   59.8±10.48 0.803
Body mass index (kg/m
2) 22.5±2.36 22.0±3.02 0.461
Cigarette smoking (%) 41.7 22.8 0.162
Cause of ESRD (%)
   Diabetes mellitus
   Hypertension
   Glomerulonephritis
   ADPKD
   Urologic disease
   Other
   Unknown
25
0
31.3
  6.3
0
  6.3
31.3
  6.5
13.3
31.4
  2.2
  1.2
  8.5
37
0.094
Comorbidities before  
   transplantation (%)
   Diabetes mellitus
   Hypertension
   Ischemic heart disease
   Cerebrovascular accident
   Dyslipidemia
31.3
87.5
12.5
0
33.3
  8.9
91.4
  3.4
  2.4
28.1
0.014
0.642
0.180
1.000
0.747
Left ventricular dysfunction* (%) 37.5   5.8 0.011
Donor age (yr)    36±12.1    37±11.2 0.798
Living donor (%) 81.3 84.5 0.724
Preemptive Transplantation (%) 0 17.1 0.086
Duration of RRT (months)   52.1±43.69   29.9±42.23 0.041
Use of FK-506 (%) 18.8 44.1 0.069
Acute rejection (%) 31.3 24.8 0.561
PTDM (%) 45.5 15 0.019
GFR at 1 yr (mL/min)   72.0±13.83   63.3±14.74 0.044
Data are expressed as mean±SD or percentage. 
*Left ventricular dysfunction was defined as ejection fraction <45%.
ESRD, end stage renal disease; ADPKD, autosomal dominant polycystic kidney disease; 
PTDM, post-transplantation diabetes mellitus; CsA, cyclosporine A; RRT, renal replace- 
ment therapy; GFR, glomerular filtration rate.
Table 3. Univariate analysis of risk factors predicting cardiovascular disease after 
renal transplantation
Variables Hazard ratio 95% CI       P
Age by 10 yr 1.970 1.253-3.096 0.002
Male gender 0.810 0.281-2.335 0.696
BMI 1.075 0.920-1.257 0.366
Cigarette smoking 2.092 0.661-6.622 0.209
Diabetes mellitus 8.803 2.830-27.383 <0.001
PTDM*  4.373 1.318-14.506 0.016
Hypertension 0.694 0.157-3.067 0.630
Ischemic heart disease 1.142 0.687-1.899 0.610
Dyslipidemia 1.019 0.301-3.454 0.976
Ejection fraction <45% 9.725 2.306-41.008 0.002
Deceased donor   1.139 0.324-4.003 0.840
Donor age 0.991 0.948-1.035 0.681
Preemptive transplantation 0.037 0.000-11.296 0.259
Duration of RRT by 5 yr
† 2.088 1.243-3.507 0.005
Use of FK-506 0.436 0.121-1.573 0.205
Acute rejection 1.396 0.484-4.023 0.537
Serum Creatinine at 1 yr 0.077 0.008-0.780 0.030
GFR at 1 yr 1.026 0.992-1.061 0.133
*Patients with diabetes mellitus before transplantation were excluded; 
†Preemptive 
transplantation was considered as zero month of RRT duration.
CI, Confidence interval; BMI, body mass index; PTDM, post-transplantation diabetes 
mellitus; RRT, renal replacement therapy; GFR, glomerular filtration rate.Jeong JC, et al.  •  Cardiovascular Diseases after Kidney Transplantation
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smoking, cause of ESRD, donor age, donor type, preemptive 
transplantation, type of calcineurin inhibitor and acute rejec-
tion indicated no significant difference. 
Risk factors for cardiovascular disease 
Table 3 gives a result of univariate Cox regression analysis. In 
univariate analysis, older age (hazard ratio [HR] 1.970, 95% con-
fidence interval [CI] 1.253-3.096, P=0.001), presence of diabetes 
mellitus (HR 8.803, 95% CI 2.830-27.383, P<0.001), occurrence 
of PTDM (HR 4.373, 95% CI 1.318-14.506, P=0.016), left ventric-
ular dysfunction (HR 9.725, 95% CI 2.306-41.008, P=0.002) and 
longer duration of RRT (HR 2.088, 95% CI 1.243-3.507, P=0.005) 
were significantly associated with CVD. In contrast, there was 
no association with recipient’s gender, BMI, cigarette smoking, 
hypertension before transplantation, IHD before transplanta-
tion and dyslipidemia. Among non-traditional risk factors, do-
nor type, donor age, preemptive transplantation, use of FK-506 
and acute rejection showed no significant association with CVD. 
  Table 4 shows a result of multivariate analysis. LV dysfunction 
and cigarette smoking were excluded from multivariate risk mod-
el because of missing data rates. Age (HR 1.843 P=0.048), dura-
tion of renal replacement therapy (HR 3.394, P<0.001) and either 
presence of diabetes mellitus or occurrence of PTDM (HR 3.846, 
P=0.046) were independent risk factors of cardiovascular dis-
ease after renal transplantation. 
  Fig. 2 is a Kaplan-Meier curve which depicts occurrence of 
cardiovascular disease according to diabetes status (diabetes 
before transplantation group, PTDM group and non-diabetes 
group). In Fig. 2, CVD tends to occur in the later period in PTDM 
group. Median time interval from transplantation to CVD was 
122 months in PTDM group. (Diabetes vs PTDM vs non-diabe-
tes, 14 months: 122 months: 40 months, P<0.001) In addition, 
CVD also tends to occur in the later period in PTDM group com-
pared with diabetes mellitus group (P=0.025).
DISCUSSION
Our study shows the significantly lower incidence of CVD than 
previous reports: the cumulative incidence of CVD was 11.4% 
at 12 yr after transplantation in our cohort. This result could be 
attributed to the lower prevalence of diabetes mellitus. The prev-
alence of diabetes in a previous report from the United States 
was 44.7%. Our study population included 9.8% of diabetes pa-
tients, nearly one fifth of USRDS data (4). In addition, the low 
incidence might be related to ethnic disparity. A prevalent risk 
factor itself may not be sufficient to predict a high CVD incidence 
in Asian population. For example, in a study to compare the ob-
served coronary heart disease rate with predicted coronary heart 
disease rate in Chinese population, the observed coronary heart 
disease rate was only one sixth of predicted rate calculated by 
Framingham function (11). 
  For renal transplantation recipients, diabetes seems to have 
special importance. In a corner stone study that compared the 
CVD risk factors of renal transplant recipients to that of the Fram-
ingham Heart Study (FHS) population, risk of IHD associated 
with diabetes mellitus was substantially higher for renal trans-
plant recipients than for the FHS population. It was postulated 
that an advanced form of diabetes mellitus (e.g., longer dura-
tion of diabetes mellitus, poor glycemic control and unknown 
genetic susceptibility of microvasculature) may have been more 
prevalent among renal transplant recipients than among diabet-
ic patients in the FHS cohort, because diabetes mellitus in renal 
transplant recipients had already caused ESRD (12, 13). PTDM 
has been reported to be associated with cardiovascular risk in 
renal recipients (14, 15). Our study also proved PTDM as a CVD 
risk factor. Furthermore, in our study, CVD tended to occur in 
later periods in PTDM group, which suggests a possibility that 
the cumulative effect of hyperglycemia on the occurrence of 
CVD. Since PTDM is a common comorbidity after renal trans-
plantation, about 10% of prevalence (16), it is worth investigat-
ing prospectively whether optimal management of PTDM re-
duces CVD occurrence. 
  Left ventricular dysfunction was a significant risk factor in 
univariate analysis, although it was omitted from multivariate 
Table 4. Multivariate analysis of risk factors predicting cardiovascular disease after 
renal transplantation
Variables Hazard ratio 95% CI   P 
Age 1.843 1.005-3.381 0.048
DM or PTDM 3.846 1.025-14.432 0.046
Use of FK-506 0.426 0.097-1.873 0.259
Duration of RRT by 5 yr 3.394 1.728-6.665 <0.001
GFR at 1 yr 1.011 0.972-1.050 0.597
CI, Confidence interval; DM, diabetes mellitus; PTDM, post-transplantation diabetes 
mellitus; RRT, renal replacement therapy; GFR, glomerular filtration rate.
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Fig. 2. Differences in the cumulative incidence of cardiovascular disease according 
to diabetes status. Median time interval from transplantation to CVD was significantly 
different between groups. (Diabetes vs PTDM vs non-diabetes, 14 months: 122 months: 
40 months, P<0.001, Log rank test).
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analysis because missing rates were too high (27.3% of missing 
rates). However, it may have some clinical significance. Since 
neuropathy is common in diabetes or ESRD patients, asymptom-
atic IHD could occur. A low ejection fraction detected by echo-
cardiography could reflect the sequelae of silent IHD. A longer 
duration of RRT before transplantation was associated with a 
higher incidence of CVD, which is consistent with the previous 
report (17). It was suggested that there is an association of long 
term dialysis with the inflammatory biomarker and vascular cal-
cification (18, 19). However, it is the limitation of this study that 
there were no additional biochemical data to link the duration 
of RRT to the risk of CVD. Preemptive transplantation was neg-
atively correlated with CVD occurrence in univariate analysis. 
Several previous studies included dialysis duration as covariates 
and two studies reported lower CVD occurrence in preemptive 
transplantation group in univariate analysis (4, 5). No previous 
study proved the preemptive transplantation as an independent 
negative risk factor. Neither hypertension nor dyslipidemia was 
a significant risk factor in our study. By definition, all patients 
who used anti-hypertensive drugs or statins were regarded as 
hypertensive patients or dyslipidemic patients. The very high 
prevalence of hypertension irrespective of CVD and use of active 
medications might reduce the significance of these comorbidi-
ties as risk factors. 
  FK-506 has been reported to improve cardiovascular risk pro-
file (9, 20, 21). At the same time, FK-506 has been demonstrated 
to increase the rate of occurrence of PTDM. Although an im-
proved cardiovascular risk profile has been shown in several 
reports, only a single study showed that the use of FK-506 actu-
ally reduces the observed incidence of CVD (22). We performed 
subgroup analysis to establish cardiovascular risk of FK-506 in 
non-diabetic patients. However, it did not demonstrate the dif-
ference (data not shown). One plausible explanation is that the 
occurrence of PTDM could offset the beneficial effect to lipid 
profile in FK-506 treated patients. It should be established by a 
long term prospective study. 
  In summary, this is the first study about the incidence of CVD 
and its risk factors in Korean renal transplant recipients: the cu-
mulative incidence of CVD after renal transplantation is 11.4% 
at 12 yr. Independent predictive factors associated with the oc-
currence of CVD include advanced age, prolonged duration of 
RRT and either presence of diabetes mellitus or occurrence of 
PTDM. 
REFERENCES
1. Kim SM, Lee C, Lee JP, Kim EM, Ha J, Kim SJ, Park MH, Ahn C, Kim YS. 
Kidney transplantation in sensitized recipients; a single center experi-
ence. J Korean Med Sci 2009; 24 Suppl: S143-7.
2. Yoon HE, Hyoung BJ, Hwang HS, Lee SY, Jeon YJ, Song JC, Oh EJ, Park 
SC, Choi BS, Moon IS, Kim YS, Yang CW. Successful renal transplanta-
tion with desensitization in highly sensitized patients: a single center ex-
perience. J Korean Med Sci 2009; 24 Suppl: S148-55.
3. USRDS. USRDS 2008 Annual report. Available at http://www.usrds.
org/2008/pdf/V2_07_2008.pdf [accssed on 28 September 2009].
4. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of 
myocardial infarction after kidney transplantation. J Am Soc Nephrol 
2005; 16: 496-506.
5. Vanrenterghem YF, Claes K, Montagnino G, Fieuws S, Maes B, Villa M, 
Ponticelli C. Risk factors for cardiovascular events after successful renal 
transplantation. Transplantation 2008; 85: 209-16.
6. Harland JO, Unwin N, Bhopal RS, White M, Watson B, Laker M, Alberti 
KG. Low levels of cardiovascular risk factors and coronary heart disease 
in a UK Chinese population. J Epidemiol Community Health 1997; 51: 
636-42.
7. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, Klag 
MJ, Mailloux LU, Manske CL, Meyer KB, Parfrey PS, Pfeffer MA, Wenger 
NK, Wilson PW, Wright JT Jr. Controlling the epidemic of cardiovascular 
disease in chronic renal disease: what do we know? What do we need to 
learn? Where do we go from here? National Kidney Foundation Task 
Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
8. Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kid-
ney transplantation. J Am Soc Nephrol 2006; 17: 900-7.
9. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, 
Blom HJ, Sweep FC, Demacker PN, Hilbrands LB. Improved cardiovas-
cular risk profile and renal function in renal transplant patients after ran-
domized conversion from cyclosporine to tacrolimus. J Am Soc Nephrol 
2003; 14: 1880-8.
10. Kim HW, Kang SW, Lee HY, Choi DH, Shim WH, Kim SI, Kim YS, Choi 
KH. Correlates of the severity of coronary atherosclerosis in long-term 
kidney transplant patients. J Korean Med Sci 2010; 25: 706-11.
11. Liu J, Hong Y, D’Agostino RB Sr, Wu Z, Wang W, Sun J, Wilson PW, Kan-
nel WB, Zhao D. Predictive value for the Chinese population of the Fram-
ingham CHD risk assessment tool compared with the Chinese Multi-Pro-
vincial Cohort Study. JAMA 2004; 291: 2591-9.
12. Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kan-
nel WB. Prediction of coronary heart disease using risk factor categories. 
Circulation 1998; 97: 1837-47.
13. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic 
heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 
11: 1735-43.
14. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, 
Stegall MD. New onset hyperglycemia and diabetes are associated with 
increased cardiovascular risk after kidney transplantation. Kidney Int 
2005; 67: 2415-21.
15. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after 
kidney transplantation in the United States. Am J Transplant 2003; 3: 
178-85.
16. Shah T, Kasravi A, Huang E, Hayashi R, Young B, Cho YW, Bunnapra-
dist S. Risk factors for development of new-onset diabetes mellitus after 
kidney transplantation. Transplantation 2006; 82: 1673-6.
17. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik 
DM, Leichtman AB, Kaplan B. Effect of waiting time on renal transplant 
outcome. Kidney Int 2000; 58: 1311-7.
18. Mallamaci F, Tripepi G, Cutrupi S, Malatino LS, Zoccali C. Prognostic 
value of combined use of biomarkers of inflammation, endothelial dys-Jeong JC, et al.  •  Cardiovascular Diseases after Kidney Transplantation
1594   http://jkms.org DOI: 10.3346/jkms.2010.25.11.1589
function, and myocardiopathy in patients with ESRD. Kidney Int 2005; 
67: 2330-7.
19. Hernandez D, Rufino M, Bartolomei S, Gonzalez-Rinne A, Lorenzo V, 
Cobo M, Torres A. Clinical impact of preexisting vascular calcifications 
on mortality after renal transplantation. Kidney Int 2005; 67: 2015-20.
20. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular 
risk factors in renal transplant patients: cyclosporin A versus tacrolimus. 
J Am Soc Nephrol 2001; 12: 368-73.
21. Morales JM, Dominguez-Gil B. Impact of tacrolimus and mycopheno-
late mofetil combination on cardiovascular risk profile after kidney trans-
plantation. J Am Soc Nephrol 2006; 17: S296-303.
22. Shihab FS, Waid TH, Conti DJ, Yang H, Holman MJ, Mulloy LC, Henning 
AK, Holman J Jr, First MR. Conversion from cyclosporine to tacrolimus 
in patients at risk for chronic renal allograft failure: 60-month results of 
the CRAF Study. Transplantation 2008; 85: 1261-9.